Staying up to date on COVID-19 vaccines is the single most effective step you can take to lower your odds of developing long COVID, with pooled data from multiple studies showing that vaccinated people face roughly a quarter lower risk than unvaccinated people. But vaccination is not the whole story. A combination of strategies, from early antiviral treatment to avoiding repeat infections, can meaningfully shift your risk profile. The science on long COVID prevention has matured considerably since 2020, and while no approach guarantees protection, the evidence points to several layers of defense worth understanding.
Vaccination Remains the Strongest Shield
The most consistent finding across long COVID research is that vaccination before infection reduces the chance of lingering symptoms. A 2023 systematic review in BMJ Medicine examined twelve studies on pre-infection vaccination and found that ten showed a significant reduction in long COVID incidence. The odds of developing long COVID after one dose ranged widely, but two doses consistently brought the risk down, and one study found that three doses before infection cut the odds to about a sixth of the unvaccinated baseline.1PubMed Central. Effect of covid-19 vaccination on long covid: systematic review
A larger meta-analysis published in Nature Communications in 2025 put sharper numbers on this. Across ten studies, vaccinated individuals had roughly 23% lower odds of long COVID compared to unvaccinated people. Booster doses added further protection, bringing odds down by about 26% compared to no vaccination. Boosters also outperformed the primary two-dose course alone, suggesting that each additional dose chips away at risk a bit more.2Nature Communications. A systematic review and meta-analysis of the impact of vaccination on prevention of long COVID
These are population-level averages, of course. Individual protection varies with age, immune status, the variant circulating at the time, and how long it has been since your last dose. But the direction of the evidence is clear and consistent: if you get infected after being vaccinated, your body handles the virus more efficiently, which appears to reduce the kind of sustained immune disruption that drives long COVID.
Hybrid Immunity and Why Prior Infection Matters
If you have been both vaccinated and previously infected, you may have an even stronger buffer. A 2025 study of healthcare workers found that hybrid immunity, the combination of vaccination and a confirmed prior infection, reduced long COVID risk by 81% to 92%. That protection held regardless of how many vaccine doses someone had received, which variant caused their prior infection, or how long ago their last immune event occurred (up to nine months).3Clinical Infectious Diseases. Hybrid Immunity Significantly Reduces Long COVID Risk in Health Care Workers
There is a wrinkle, though. A Czech study tracking Omicron-era infections found that while hybrid immunity and post-infection immunity provided strong protection against severe acute COVID, the protective effect against long COVID specifically was more modest once someone was actually reinfected. In other words, previous immunity helps prevent severe disease and likely reduces viral persistence, but it may not fully eliminate the risk of lingering symptoms once a new infection takes hold.4PubMed Central. Post-vaccination, post-infection and hybrid immunity against severe cases of COVID-19 and long COVID after infection with SARS-CoV-2 Omicron subvariants, Czechia, December 2021 to August 2023
Avoiding Reinfection Is Underrated
Each time you catch COVID, you roll the dice again on long COVID. A study of children and adolescents found that reinfection roughly doubled the overall risk of a long COVID diagnosis and increased the risk of specific complications, from fatigue and cognitive impairment to heart-related conditions, by anywhere from 15% to over three and a half times the baseline.5The Lancet Infectious Diseases. Post-acute sequelae of SARS-CoV-2 infection in children and adolescents after reinfection Earlier research in adults using electronic health records pointed in the same direction, linking reinfection to higher rates of post-acute problems including organ-specific damage, though some of that data came from a military veteran population that may not perfectly represent the broader public.6PubMed Central. Risk of New-Onset Long COVID Following Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2: A Community-Based Cohort Study
The practical takeaway is unglamorous: basic infection prevention still matters. Staying current on vaccines, avoiding crowded indoor settings when transmission is high, and improving ventilation where you can all reduce the number of times the virus gets a crack at your immune system. People who have already had long COVID have particular reason to be cautious, since a second or third infection could re-trigger or worsen symptoms.
Early Antiviral Treatment During Acute Infection
If you do get infected, starting treatment quickly may reduce the severity of what follows. Paxlovid (nirmatrelvir-ritonavir) has been the most widely studied antiviral in this context, but the results are more nuanced than early headlines suggested. A large target trial emulation using data from the N3C and RECOVER consortia found that Paxlovid did not significantly reduce overall long COVID incidence. It did, however, show a small protective effect against cognitive symptoms and fatigue specifically.7PubMed Central. Effect of Paxlovid treatment during acute COVID-19 on Long COVID onset: An EHR-based target trial emulation from the N3C and RECOVER consortia
The benefits appear to be more pronounced in older adults. Among non-hospitalized patients aged 65 to 75, Paxlovid was associated with roughly a 17% reduction in overall long COVID risk. In younger groups, the effect was not statistically significant.8Communications Medicine. Paxlovid shows organ-specific and age-specific impacts on risk of developing post-acute sequelae of COVID-19 So Paxlovid is not a universal long COVID preventer, but for people over 65 who test positive, there is a reasonable case that early treatment could help.
Metformin as a Surprising Contender
One of the more unexpected findings in long COVID prevention involves metformin, the widely used diabetes drug. The COVID-OUT trial, a randomized, placebo-controlled study, found that people who received metformin during acute COVID had roughly 40% lower odds of developing long COVID over the following ten months. When metformin was started within three days of symptom onset, the reduction was even steeper, with the risk dropping by about 63%.9The Lancet Infectious Diseases. Outpatient treatment of COVID-19 and incidence of long COVID over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial
Those numbers are striking, but there are important caveats. A systematic review and meta-analysis of metformin trials noted that the long COVID benefit rests on a single trial of about 1,100 patients, which had a high risk of bias from missing data. Nearly half of the participants in that trial were also unvaccinated, which makes it harder to know how much metformin would help in today’s largely vaccinated population.10PubMed Central. Metformin for covid-19: systematic review and meta-analysis of randomised controlled trials Metformin is cheap, widely available, and well-tolerated, so it could eventually become part of standard early treatment. But larger confirmatory trials are needed before it can be broadly recommended for this purpose.
Who Faces Higher Risk in the First Place
Understanding your baseline risk helps you decide how aggressively to pursue prevention. Several factors consistently predict who is more likely to develop long COVID after infection.
Even mild infections carry real risk. A cohort study found that about 30% of people with mild COVID reported at least one residual symptom a month later, compared to 6% of people with non-COVID respiratory illness during the same period. Risk rose with age, with people over 50 facing roughly two and a half times the odds compared to those aged 15 to 30. Having more than five symptoms during the acute phase tripled the odds of developing long COVID, and women showed a trend toward higher risk as well.11PubMed Central. Prevalence and risk factors for long COVID after mild disease: A cohort study with a symptomatic control group
A nationwide cohort study confirmed that even mild infections carry elevated risk for specific problems months later, including loss of taste and smell, cognitive impairment, shortness of breath, weakness, and palpitations. These risks were highest in the first few months but remained significantly elevated even in the later period beyond 180 days.12BMJ. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study The severity of your acute illness does predict risk to some extent, with hospitalized patients facing higher odds. But the idea that only severe cases lead to long COVID is a misconception. People with asymptomatic or mild infections develop it too.13PubMed Central. Long COVID: An inevitable sequela of SARS-CoV-2 infection
Why Women Are Disproportionately Affected
Women develop long COVID at higher rates than men, and the reasons appear to be partly hormonal. A review in JAMA Network Open noted that differences in estrogen and other sex hormone levels modulate immune responses in ways that may make women under 55 more susceptible. Low estrogen levels favor a type of immune response that drives inflammation, while higher levels shift the balance toward antibody-based immunity. These hormonal fluctuations may influence how aggressively and how long the immune system stays activated after infection.14JAMA Network Open. Sex Differences in Long COVID
Research in Science Translational Medicine added molecular detail. Women who went on to develop long COVID showed increased expression of an RNA gene called XIST during acute infection, a gene that has been implicated in autoimmunity. Men who developed long COVID, by contrast, showed elevated activity in a different immune signaling pathway. The immune routes to long COVID appear to differ by sex, which may eventually matter for treatment but already helps explain why the condition affects women more often.15PubMed Central. Sex differences and immune correlates of Long Covid development, symptom persistence, and resolution
Variant Evolution Has Helped, but Not Enough
The virus itself has changed in ways that affect long COVID risk. A study in the New England Journal of Medicine compared post-acute outcomes across pandemic eras and found that among unvaccinated people, the cumulative incidence of long COVID dropped from about 10.4 per 100 infections in the pre-Delta period to roughly 7.8 per 100 in the Omicron era.16PubMed Central. Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras That is a meaningful decline but still far from zero.
A head-to-head comparison of Omicron and Delta infections found that long-term complaint rates were similar for many symptoms, including fatigue, brain fog, and heart palpitations. However, at 90 days and beyond, Omicron infections produced fewer overall complaints and less musculoskeletal pain than Delta.17Nature Communications. Post-covid medical complaints following infection with SARS-CoV-2 Omicron vs Delta variants The shift toward milder variants is welcome, but it should not create a false sense of security. Omicron-era infections still produce long COVID at rates that matter, especially when multiplied across hundreds of millions of infections worldwide.
What to Do During and After an Acute Infection
Beyond medication, how you handle the acute illness may influence what comes after. Pushing through a COVID infection without rest is a common mistake. Research on post-exertional symptom exacerbation, the hallmark crash that many long COVID patients experience when they overdo it, suggests that structured pacing during and after acute illness can reduce symptom burden. A prospective cohort study of patients using a pacing and active rest protocol found that the approach reduced the frequency and duration of symptom flare-ups, with participants reporting fewer and milder symptoms over an eight-week period.18PubMed Central. A Personalised Pacing and Active Rest Rehabilitation Programme for Post-Exertional Symptom Exacerbation and Health Status in Long COVID (PACELOC): A Prospective Cohort Study
The lesson for prevention is straightforward: if you test positive, rest genuinely. Do not return to exercise, heavy work, or stressful obligations the moment your fever breaks. Gradual re-engagement with activity, guided by how your body responds rather than a calendar deadline, may reduce the chance of tipping into a longer recovery.
Emerging Leads in Prevention and Treatment
Several areas of research are generating interest even though they are not yet at the level of firm clinical recommendations.
Antihistamines have shown preliminary promise. A study on long COVID patients with symptoms attributed to mast cell activation found that blocking both H1 and H2 histamine receptors improved cardiovascular and other symptoms, and long COVID symptoms disappeared entirely in about 29% of treated patients.19PubMed Central. Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation This is a treatment finding rather than a prevention finding, but it hints at the immune pathways involved and raises the question of whether early use of antihistamines during acute infection might dampen the inflammatory cascade that leads to prolonged symptoms. Larger trials are underway.
The connection between COVID-19 and Epstein-Barr virus (EBV) reactivation is another thread worth watching. Many people carry dormant EBV from childhood infections, and COVID appears to trigger its reactivation in some individuals. Researchers have proposed that this reactivation may drive autoimmune responses and contribute to immune-related long COVID symptoms.20PubMed. COVID-19, Epstein-Barr virus reactivation and autoimmunity: Casual or causal liaisons? If this link is confirmed, it could open the door to screening high-risk patients for EBV reactivation markers and intervening early with antiviral or immune-modulating therapies.
Vitamin D status has also attracted attention. An umbrella review of studies found that COVID-19 patients with vitamin D levels below 20 to 30 ng/mL had roughly double the odds of severe illness and triple the odds of dying compared to those with higher levels.21PubMed Central. The role of vitamin D in prevention of COVID-19 and its severity: an umbrella review The link between severe acute infection and long COVID risk is well established, so maintaining adequate vitamin D levels is a reasonable general measure. It is cheap and safe for most people. Whether supplementation directly prevents long COVID independent of its effect on acute severity is still unclear.
Long COVID in Children and Adolescents
Children are not immune to long COVID, despite early assumptions that the virus would pass through younger populations without lasting effects. A meta-analysis of 40 studies found that about 23% of children and adolescents who had COVID developed some form of lingering symptoms. The most common were generalized symptoms like fatigue (about 20%), respiratory complaints including shortness of breath (about 23%), and neurological symptoms including headache (about 16%). Psychiatric symptoms, including anxiety and depression, were reported in about 12% of cases.22PubMed Central. Prevalence and risk factor for long COVID in children and adolescents: A meta-analysis and systematic review
For parents, the prevention strategies are the same: keep vaccinations current where eligible, reduce unnecessary exposures during high-transmission periods, and allow genuine rest during and after infection. The pediatric reinfection data cited earlier makes these precautions especially relevant for children who have already had COVID once.
Occupational and Socioeconomic Dimensions
Your job can influence your long COVID risk in ways that go beyond simple exposure. An analysis of the UK’s Coronavirus Infection Survey found wide variation in long COVID prevalence by occupation. People working in caring, leisure, and service roles had substantially elevated odds compared to average, while those in financial services had the lowest prevalence. Teaching and education workers reported some of the highest rates of severe functional impairment, with about 22% to 23% reporting that long COVID reduced their function “a lot.”23PubMed Central. Occupational differences in the prevalence and severity of long-COVID: analysis of the Coronavirus (COVID-19) Infection Survey
These patterns reflect a mixture of exposure risk, physical demands, and the ability to rest during illness. Workers who cannot take time off, who interact closely with many people daily, or whose roles involve physical exertion are both more likely to get infected repeatedly and less able to recover fully when they do. Workplace policies around sick leave, ventilation, and remote work options are not usually framed as long COVID prevention, but they function as exactly that.
The Gut Microbiome Connection
The gut’s role in long COVID has become an active area of research. SARS-CoV-2 enters cells through a receptor that also plays a key role in regulating gut bacteria and vascular function. When the virus disrupts this receptor’s normal activity, it can throw gut microbial balance off in ways that have been linked to a range of long COVID symptoms, including brain fog, fatigue, joint pain, and mood disturbances.24PubMed Central. Role of Gut Microbiota in Long COVID: Impact on Immune Function and Organ System Health Long COVID shares many features with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and the two conditions overlap in their effects on the immune system, energy metabolism, and gut microbiome.25PubMed Central. ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature
What this means for prevention is still speculative, but it suggests that supporting gut health through a varied diet rich in fiber and fermented foods is unlikely to hurt and may help maintain the kind of microbial diversity that supports immune resilience. Researchers are exploring whether probiotic or prebiotic interventions during or after acute COVID could reduce long-term symptoms, but no clinical trial has yet produced definitive results on this front.